[Follow-up in breast carcinoma].
Sinha
C
C
Klinik und Poliklinik für InnereMedizin, Universitätsspital Zürich, Stadtspital Triemli Matérnite. chanal.sinha@usz.ch
Köhler
H
H
Fink
D
D
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008327:Mammography; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010166:Palliative Care; D011379:Prognosis; D013902:Radiography, Thoracic; D011877:Radionuclide Imaging; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D016217:Ultrasonography, Mammary
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen